Company intelligence / Profile preview
Aqilion
Helsingborg, Skåne, Sweden
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Aqilion has successfully completed a Phase I study with its lead candidate AQ280 (“Regulus” program) showing good tolerability and pharmacokinetics. The company’s pipeline includes several preclinical programs targeting kinases involved in chronic inflammation. A previous partnership with Merck KGaA on TAK1 inhibitors was terminated after new data altered the risk-benefit profile, but the collaboration validated Aqilion’s business model of generating high-quality early-stage assets.[3][5][10]
The company is preparing to initiate Phase II trials for eosinophilic esophagitis with market potential exceeding $1 billion.[6]
Overall, Aqilion focuses on advancing projects from idea to proof-of-concept before seeking partners or acquirers.
- Therapeutic areas
- GastroenterologyImmunology
- Modalities
- Small molecules (focus on kinase inhibitors and related drug classes)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Merck KGaA — exclusive license/collaboration deal signed Feb. 2023 for TAK1 inhibitors, later terminated June 2024 when rights reverted to Aqilion due to risk-benefit concerns discovered during joint research. Deal included €10M upfront payment plus milestones up to €950M if successful.[5][10]
Beyond the preview
Go deeper on Aqilion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aqilion.